What is ALN-SOD?
ALN-SOD is an experimental drug that is being developed to treat SOD1-MND/ALS. ALS-SOD is part of a class of therapies known as R interference drugs. These drugs are designed to reduce or silence the production of faulty SOD1 proteins. Which is believed to play a harmful role in motor neuron damage and disease progression in people with SOD1 MND/ALS.
The aim of ALS-SOD is to lower levels of the toxic SOD1 protein, potentially slowing the progression of MND and preserving muscle function.
The study is also investigating:
- How the drug affects biomarkers in blood and cerebrospinal fluid (CSF)
- How much of the drug is present in the body overtime.
- Whether the body produces antibodies against it.
- How it impacts MND/ALS symptoms.
Eligibility Criteria:
- Aged 18 years or older
- Male or female (with strict contraception if childbearing potential)
- Diagnosed with MND/ALS confirmed by trial doctors
- Mild MND symptoms (ALSFRS-R score of 30 or higher)
- MND/ALS symptoms began within last 24 months.
- Not currently treated for ALS or on stable does of riluzole or edaravone.
- Able to exhale at least 60% of the expected lung capacity based on sex, height and age.
| NSW | Concord Repatriation General Hospital Macquarie University Hospital | Universal Contact: Clinical Trials Administrator 844-734-6643 clinicaltrials@regeneron.com |
Want to know more information?
For more information Visit Study Details | NCT06351592 | First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) | ClinicalTrials.gov